ANCA-associated Vasculitis Clinical Trial
— AvacostarOfficial title:
Avacostar - A Post Authorization Safety Study (PASS) to Evaluate the Incidence of Safety Events of Interest in Patients Treated With Avacopan for ANCA-associated Vasculitis (AAV)
The Avacostar PASS is a non-interventional, multi-national, prospective cohort study that will collect data from 2 cohorts of patients: those treated with avacopan for active severe AAV, and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV. The overall study duration is anticipated to be up to 7 years, including a recruitment period of approximately 3 years.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | December 1, 2030 |
Est. primary completion date | December 1, 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of AAV (MPA or GPA), as determined by the Investigator according to their usual practice. - Active, severe AAV at the time of commencing avacopan or non-avacopan SoC induction therapy, in the opinion of the Investigator. - Age =18 years of either sex. - Has provided written informed consent. - Has commenced within the previous 6 months, or is planned to commence avacopan, cyclophosphamide or rituximab for the treatment of severe, active AAV outside of an interventional clinical study. Exclusion Criteria: • Concurrent participation in an interventional study, unless prospectively discussed and agreed with the Medical Monitor. |
Country | Name | City | State |
---|---|---|---|
Germany | Charité University Medicine | Berlin | |
Germany | University Hospital of Cologne | Cologne | |
Germany | Municipal Hospital Dresden | Dresden | |
Germany | University Hospital Essen | Essen | |
Germany | University Hospital Freiburg | Freiburg | |
Germany | University Medical Center Göttingen | Göttingen | |
Germany | University Hospital Eppendorf | Hamburg | |
Germany | KRH Klinikum Siloah | Hannover | |
Germany | Rheumazentrum Ruhrgebiet | Herne | |
Germany | LMU | Munich | |
Germany | Medius Kliniken | Plochingen | |
Germany | St. Josef-Stift Sendenhorst | Sendenhorst | |
United Kingdom | UHB NHS Foundation Trust | Birmingham | |
United Kingdom | Bradford Teaching Hospitals NHS Foundation Trust | Bradford | |
United Kingdom | North Bristol NHS Trust | Bristol | |
United Kingdom | Addenbrookes Hospital | Cambridge | |
United Kingdom | East Kent Hospitals University NHS FT | Canterbury | |
United Kingdom | Cardiff and Vale UHB | Cardiff | |
United Kingdom | Epsom & St. Helier NHS Trust | Carshalton | |
United Kingdom | University Hospitals Coventry and Warwickshire | Coventry | |
United Kingdom | Royal Devon University Healthcare NHS Foundation Trust | Exeter | |
United Kingdom | NHS Greater Glasgow & Clyde | Glasgow | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | Barts Health | London | |
United Kingdom | Hammersmith Hospital, Imperial College Healthcare NHS Trust | London | |
United Kingdom | Kings College Hospital | London | |
United Kingdom | Royal Free | London | |
United Kingdom | St Thomas' Hospital | London | |
United Kingdom | Manchester University NHS Foundation Trust | Manchester | |
United Kingdom | Nottingham university hospitals NHS trust | Nottingham | |
United Kingdom | Rheumatology Department, Oxford University Hospitals NHS Foundation Trust | Oxford | |
United Kingdom | Royal Berkshire NHS foundation trust | Reading | |
United Kingdom | Northern Care Alliance | Salford | |
United Kingdom | Swansea Bay University LHB | Swansea | |
United Kingdom | York & Scarborough Teaching Hospitals NHS FT | York |
Lead Sponsor | Collaborator |
---|---|
Vifor Fresenius Medical Care Renal Pharma |
Germany, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the incidence of defined MESIs | To evaluate the incidence of defined MESIs in patients with AAV commencing avacopan. MESIs include liver injury, cardiac safety, serious infection, and malignancy. | up to 7 years | |
Secondary | Incidence rates of AE in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | AEs leading to discontinuation of therapy in the avacopan group | up to 7 years | ||
Secondary | Incidence of SAEs in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Incidence of ADRs in the avacopan group | up to 7 years | ||
Secondary | Incidence of SADRs in the avacopan group | up to 7 years | ||
Secondary | Change in eGFR over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in IgG over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in CPK over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in ALT over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in AST over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in billirubin over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change in WBC over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Change Albumin over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Time to first flare over time in the avacopan and non-avacopan groups | A flare is defined in the BVAS as a score of more than 0. No flare is defined as a BVAS score equal to 0 | up to 7 years | |
Secondary | Change in VDI scores over time in the avacopan and non-avacopan groups | up to 7 years | ||
Secondary | Incidence of MESIs in the non-avacopan group | up to 7 years | ||
Secondary | Incidence rates of SAEs and MESIs in the avacopan group compared to the non-avacopan group, | up to 7 years | ||
Secondary | Incidence rates of MESIs in the avacopan group compared to the non-avacopan group, | up to 7 years | ||
Secondary | Use of concomitant immunosuppression over time and cumulative by treatment group, | up to 7 years | ||
Secondary | Duration of GC-free periods | up to 7 years | ||
Secondary | Proportion of GC-free patients over time by treatment group. | up to 7 years | ||
Secondary | Duration of treatment with avacopan by reason for treatment discontinuation. | up to 7 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02257866 -
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
|
||
Completed |
NCT02463539 -
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
|
N/A | |
Recruiting |
NCT05364892 -
Biocollection of Patients With ANCA Associated Vasculitis
|
N/A | |
Terminated |
NCT00482066 -
Abatacept in ANCA Associated Vasculitis
|
Phase 2 | |
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Recruiting |
NCT05965284 -
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
|
Phase 4 | |
Recruiting |
NCT06285279 -
FKC288 in Participants With Autoimmune Kidney Diseases
|
Phase 1 | |
Completed |
NCT02994927 -
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
|
Phase 3 | |
Recruiting |
NCT02463578 -
Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
|
N/A | |
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Recruiting |
NCT05383573 -
Pediatric ANCA Associated-vasculitis
|
||
Completed |
NCT02222155 -
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
|
Phase 2 | |
Recruiting |
NCT05197842 -
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
|
Phase 1/Phase 2 | |
Completed |
NCT02954705 -
MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
|
||
Completed |
NCT04280601 -
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
|
N/A | |
Active, not recruiting |
NCT02108860 -
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
|
Phase 3 |